ClinicalTrials.gg
CompletedNCT03355222Updated Nov 3, 2020

Using Eggshell Calcium to Mitigate Fluorosis in Ethiopia

An interventional study of Promotion of chicken eggs in Fluoride Poisoning, Hemoglobin and Underweight, sponsored by University of Saskatchewan. Completed at 1 site in Ethiopia. Open to participants aged 6 Months to 18 Months. Per ClinicalTrials.gov, last updated 2020-11-03.

Sponsored by University of Saskatchewan · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
6 Months to 18 Months
Sex
All
01

Study summary

Mothers and young children in rural Ethiopia lack sufficient nutrition, and a compounding factor is presence of high levels of fluoride (> 5-10 mg/day) affecting body functions. Interventions involving chickens to provide eggs and eggshell (a source of calcium) are one solution. The overall purpose is to examine how increasing dietary calcium by using eggshell powder (ESP) reduces fluoride (F) absorption in women. It is known calcium binds F to prevent its absorption but application of this to a community based study has not been tested. The aim is to provide chickens to produce eggs for young children and to provide ESP to women (mothers). For children, an egg a day should improve growth and nutritional status. For women, the ESP provides calcium to reduce fluorosis and therefore improve function without affecting iron and zinc status. For the women, blood samples will be tested in a subsample for F, calcium, zinc and iron; urine samples will be measured for F, calcium and creatinine (to correct spot urine). Hemoglobin will be measured as an indicator of overall nutritional status in women and children. Nutritional status of young children (6-18 mo) and of their mothers prior and after the intervention (by 6 months) will be assessed. between 6 and 12 month there will be monitoring for sustainability of chilckens in the community; for continued use of egg (in children) and ESP (in women); during this time the control group will receive chickens and also undergo monitoring. The study will take place in the Rift valley of Southern Ethiopia. Identification of the knowledge, attitude and practices (KAP) of mothers on egg consumption will be done at baseline and at the end ("endline"). Caregivers will be instructed to give each child 1 egg (cooked) per day in the intervention, and one "bottle cap" of eggshell powder (1000 mg calcium) per day for themselves. Families receiving chickens will be instructed on cage construction. Throughout the study, any problems arising in keeping chickens will be recorded in order to assess the feasibility and practicality of raising chickens as way to mitigate fluorosis and improve nutritional status.

Read the detailed description

This is a Proof of Principle study with a treatment ("Intervention") group and a parallel control group for delivering eggshell powder to mothers in the setting of a chilken intervention. The control and intervention groups will come from the same region in southern Ethiopia where fluorosis is known to occur, with active intervention for 6 months followed by observation for a further 6 months. The Intervention is providing daily eggshell calcium to a subset of mothers, with all eligible young children receiving at least one egg a day. The treatment group consists of mothers and young children in a community where study families will receive two chickens each, and the control group are mothers and young children not having chickens for the first six months, but who will be gifted with chickens at 6 months. Along with receiving chickens, the intervention group will receive training in use of egg, as well as assistance in caring for chickens, throughout the first 6 months. In the second 6-months, the participants' use of eggs will be monitored. In the control group, provision of chickens after 6 months will be accompanied by training but for a shorter duration, and monitoring of use of egg will provide information on whether minimal support can effectively allow for adoption of new food sources into a community.

Study participants are all mothers with children aged between 6-18 months old in two participating kebeles (villages), one randomly assigned as intervention, the other as control. The age group of the child is selected because it is the time of introduction of complementary food and it will be easier to see the clear effect of egg on the children's growth. Mothers are lactating therefore at a time for maximal calcium utilization. While eggs are not commonly eaten in rural Ethiopia, it is due to expense, not to unfamiliarity. In the Intervention community prior to baseline measurements, each family of the mother-child pair will receive two chickens at a "ceremony" that marks the responsibility given to the family to provide one egg per day to the child. In a subset of mothers, they will consent to use eggshell. This is modified from what the investigators did in a pilot study (NCT02791100) and the investigators found use of egg by the child was 85% throughout the 6 month time-period. One lesson learned was to purchase older chickens that are immediately capable of laying eggs. Second, in this intervention the child will not receive ESP.

There will be formal follow-up observation at one community site with focus group discussion and key informant interviews, as a way to assess feasibility and practically of chicken donation in the future. This will be a convenience sample representing participant parents, community leaders, Agriculture Extension workers, Health extension workers, persons who were not directly involved. Those targeted for interviews will be the extension workers from whom feedback will be provided, while focus groups will be held with others who are able to attend a focus group session.

Data checks will be provided by two doctoral students working on the project. Local supervisors will provide guidance. The students have written specific operating procedures (SOP) for all procedures. Missing data will be accounted for, but as this is a community based study group means will be used for most outcome measurements. Comparing of two means/the differences of means between the intervention and control groups will be done using independent two sample t-test. Continuous outcomes will be analyzed using paired t-test. Bivariate analysis will be used to see the overall effect of independent variables and then further multivariate analysis (multiple linear regressions) will be done to see the effect of each independent variable. Both crude and adjusted risk ratio with 95% confidence interval will be reported. Other variables and relevant findings will be also analyzed using proper statistical test/analysis techniques and reported accordingly. P-value of less than 0.05 will be taken as significant

02

Conditions studied

  • Fluoride Poisoning
  • Hemoglobin
  • Underweight
  • Stunting
  • Development; Delayed, Mental
  • Fluorosis, Dental
  • Fluorosis; Skeletal
  • Zinc Deficiency

Keywords

  • complementary feeding
  • calcium
03

In context

Thinness

66 studies on the registry are indexed under Thinness; 11 are open to participants now.

This study's enrollment of 270 is close to the median of 287 across 43 interventional studies indexed under Thinness.

Browse Thinness studies →

Lead sponsor

University of Saskatchewan is the lead sponsor of 243 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • All women with a child age 6 to 18 months and their child living permanently in the village
  • the woman does not have to be biological mother Exclusion Criteria:
  • Exclude families with a child who is known to be allergic to egg
  • Exclude families with a child who is diagnosed as malnourished (moderate malnutrition (MAM) or severe malnutrition (SAM)
  • Exclude women who do not live with the child
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (actual)

Study arms

  • No intervention
    No Intervention

    No intervention: The community receives no chickens and no special education is provided.

  • Experimental
    Experimental: providing chickens and egg shell

    Experimental: Two chickens are given to each family so that eggs are available for children and of eggshell powder for mothers. The community receives these chickens so each designated family has an egg to give to young child. In a subgroup the mother will receive ESP (1000 mg calcium). The community receives information on using egg and has help on caring for chickens.

    Behavioral: Promotion of chicken eggs

Interventions

  • BehavioralPromotion of chicken eggs

    Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.

06

What researchers measure

Primary outcomes

  1. Apparent fluoride absorption

    Change in urinary fluoride corrected for creatinine as a measure of F absorption

    Time frame: 6 months

Secondary outcomes

  1. Growth in young children

    weight for age

    Time frame: 6 months and 12 months

  2. Functional indicators of fluorosis

    Physical signs of fluorosis are assessment using a standard questionnaire developed by the investigators and subsequently published (Kebede et al., 2016). Briefly this consists of a questionnaire of signs and symptoms which can be added to obtain a score

    Time frame: 6 months

  3. Hemoglobin (Hb)

    Blood levels of Hb

    Time frame: 6 months and 12 months

  4. Knowledge, attitude and practices (KAP) for egg

    Questionnaire assessment of KAP

    Time frame: 6 and 12 months

  5. Linear growth in young children

    length for age

    Time frame: 6 months and 12 months

Other outcomes

  1. Inhibition of zinc absorption

    serum zinc

    Time frame: 6 months

07

Study locations

1 site
  • Hawassa University
    Hawassa, Ethiopia
08

References and documents

Publications

  • Kebede A, N Retta, C Abuye, SJ Whiting, M Kassaw, T Zeru, MW Yohannes, D Zerfu, M Tessema, MK. Malde. Minimizing bioavailability of fluoride through addition of calcium-magnesium citrate or a calcium and magnesium-containing vegetable to the diets of growing rats. International Journal of Biochemistry Research & Review. 10(2): 1-8. 2016a
  • Kebede A, Retta N, Abuye C, Whiting SJ, Kassaw M, Zeru T, Tessema M, Kjellevold M. Dietary Fluoride Intake and Associated Skeletal and Dental Fluorosis in School Age Children in Rural Ethiopian Rift Valley. Int J Environ Res Public Health. 2016 Jul 26;13(8):756. doi: 10.3390/ijerph13080756. PubMed 27472351 ↗
  • Mulualem D, Hailu D, Tessema M, Whiting SJ. Efficacy of Calcium-Containing Eggshell Powder Supplementation on Urinary Fluoride and Fluorosis Symptoms in Women in the Ethiopian Rift Valley. Nutrients. 2021 Mar 24;13(4):1052. doi: 10.3390/nu13041052. PubMed 33804976 ↗

Individual participant data

Plan to share: No — We would find it difficult to keep records for extraction of participant data as the local language will be used to store records.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2018, 10 months.

Of 22 interventional studies with no phase under Thinness, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Nov 28, 2017
StartActual
Jan 2, 2018
Primary completionActual
Dec 1, 2018
CompletionActual
Jun 30, 2019
Last update
Nov 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03355222
Collaborators
Hawassa University
Responsible party
Susan Whiting (Professor of Nutrition, University of Saskatchewan) — Principal investigator
First posted
Nov 28, 2017
Start date
Jan 2, 2018
Primary completion
Dec 1, 2018
Completion
Jun 30, 2019
Last update
Nov 3, 2020

Study contacts

Susan Whiting, PhD
principal investigator · University of Saskatchewan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion